Clinical Trials for Other Solid Tumor

A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the combination of carfilzomib, a proteasome inhibitor, and sotorasib, a KRAS G12C inhibitor, in adults with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer who have progressed after previous KRAS inhibitor treatments.

ClinicalTrials.gov ID: NCT06249282

An Investigator-sponsored Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the efficacy of a combination of afatinib, an EGFR-targeting tyrosine kinase inhibitor, and prednisone in improving progression-free survival for patients aged 18 or older with previously treated advanced squamous non-small cell lung cancer. Enrolled patients must have an ECOG performance status of 0 or 1 and measurable disease.

ClinicalTrials.gov ID: NCT04497584

Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets patients with HER2-negative metastatic breast cancer expressing GD2, exploring treatments with gemcitabine, TGFBi NK cells, and naxitamab—an anti-GD2 monoclonal antibody—across different combinations to assess safety, efficacy, and optimal dosing.

ClinicalTrials.gov ID: NCT06026657

A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with advanced AR-positive, triple-negative breast cancer who have undergone up to three prior systemic therapies for metastatic disease, evaluating the combination of ribociclib, a CDK 4/6 inhibitor, and bicalutamide, an androgen receptor inhibitor.

ClinicalTrials.gov ID: NCT03090165

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial involves adult patients with unresectable or metastatic triple negative breast cancer, investigating a combination of rintatolimod (TLR3 pathway agonist), celecoxib, and interferon alpha-2b with pembrolizumab to enhance treatment efficacy.

ClinicalTrials.gov ID: NCT05756166

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial investigates the combination of ladarixin, a non-competitive allosteric inhibitor of CXCR1 and CXCR2, and sotorasib, a KRAS G12C inhibitor, in patients with advanced KRAS G12C mutant NSCLC who have progressed on anti-PD(L)-1 therapy and may have received platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05815173

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves previously treated adult patients with stage IV ALK positive non-small cell lung cancer, evaluating the safety and optimal dosing of gilteritinib, an investigational drug that targets the FLT3 receptor tyrosine kinase. Patients must have progressed on first and second-generation ALK TKIs and may have had chemotherapy or other antineoplastic treatments.

ClinicalTrials.gov ID: NCT06225427

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and efficacy of combining pembrolizumab, a PD-1 inhibitor, with the experimental ornithine decarboxylase inhibitor DFMO in patients aged 18 or older with Stage IV NSCLC and STK11 mutations, focusing on those who are treatment-naïve or have progressed after previous therapies.

ClinicalTrials.gov ID: NCT06219174

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced non-squamous NSCLC (Stage IV or recurrent) who progressed after maintenance therapy with pemetrexed and/or pembrolizumab, excluding those with certain mutations or untreated brain metastases. The regimen includes carboplatin and paclitaxel, standard chemotherapeutics, combined with ramucirumab, a monoclonal antibody targeting VEGFR-2 to inhibit angiogenesis.

ClinicalTrials.gov ID: NCT04332367

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of Trans-Arterial Tirapazamine Embolization (TATE) and Pembrolizumab in patients with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) who have liver metastases and have progressed after prior therapies. TATE delivers the hypoxia-activated prodrug Tirapazamine to liver tumors, while Pembrolizumab, an immune checkpoint inhibitor, blocks the PD-1 pathway to enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT04701476